In vivo administration of the S1PR2 antagonist JTE013 [64] limited osteoclastic bone resorption and reversed bone density loss in the RANKL-induced osteoporosis mouse model [67], and improved bone parameters such as bone matrix density, trabecular thickness, and trabecular density in the conventional model for postmenopausal osteoporosis in ovariectomized mice [57]. Here, S1PR2 is linked to osteoporosis.